Cardiovascular events after COVID-19 hospitalization: long-term follow-up

Negreira-Caamaño, Martín; Río, Jorge Martínez-del; Águila-Gordo, Daniel; Mateo-Gómez, Cristina; Soto-Pérez, Maeve; Piqueras‐Flores, Jesús

doi:10.1016/j.rec.2021.09.001

Cited by 6 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this increase in risk is not uniquely affecting the oldest patients [95] . Negreira-Caamano et al in their study showed that one-third of patients hospitalized between March 10th and May 4th 2020, for COVID-19 suffered from various cardiovascular events such as acute coronary syndrome, cerebrovascular event, thrombosis, hospitalization for HF and death during the first 30 days after the discharge, while one patient in sixteen during the first year after hospitalization [96] .…”

Section: Development Of Cardiovascular Complications In Post-covid-19...mentioning

confidence: 98%

“…Several studies have shown an increased risk of cardiovascular complications during the post-hospital period due to COVID-19 [9] , [95] , [96] . In comparison with the general population not exposed to SARS-CoV-2 infection, patients that were hospitalized with COVID-19 between January 1st to August 31st 2020 displayed, months after admission, higher rates of diabetes, respiratory disease, cardiovascular disease, chronic kidney and liver disease.…”

Section: Development Of Cardiovascular Complications In Post-covid-19...mentioning

confidence: 99%

See 1 more Smart Citation

Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality

et al. 2022

View full text Add to dashboard Cite

Section: Development Of Cardiovascular Complications In Post-covid-19...mentioning

confidence: 98%

Section: Development Of Cardiovascular Complications In Post-covid-19...mentioning

confidence: 99%

Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality

et al. 2022

View full text Add to dashboard Cite

“…Negreira-Caamaño et al followed up on 673 patients for 1 year after discharge for COVID-19 hospitalization. Most major cardiovascular events (acute coronary syndrome, cerebrovascular event, venous thromboembolic disease, hospitalization for heart failure, and cardiovascular death) occurred more than one month after hospitalization, although 75% of the venous thromboembolic disease cases occurred within the first 30 days [ 53 ]. Xie et al studied a cohort of 153,760 veterans who survived COVID-19 comparing it with two different cohorts, one of 5,859,411 noninfected patients during 2017 and another of 5,637,647 patients with no evidence of SARS-CoV-2.…”

Section: Long-term Cardiovascular Outcomes Of Covid-19mentioning

confidence: 99%

Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory and degenerative process that mainly occurs in large- and medium-sized arteries and is morphologically characterized by asymmetric focal thickenings of the innermost layer of the artery, the intima. This process is the basis of cardiovascular diseases (CVDs), the most common cause of death worldwide. Some studies suggest a bidirectional link between atherosclerosis and the consequent CVD with COVID-19. The aims of this narrative review are (1) to provide an overview of the most recent studies that point out a bidirectional relation between COVID-19 and atherosclerosis and (2) to summarize the impact of cardiovascular drugs on COVID-19 outcomes. A growing body of evidence shows that COVID-19 prognosis in individuals with CVD is worse compared with those without. Moreover, various studies have reported the emergence of newly diagnosed patients with CVD after COVID-19. The most common treatments for CVD may influence COVID-19 outcomes. Thus, their implication in the infection process is briefly discussed in this review. A better understanding of the link among atherosclerosis, CVD, and COVID-19 could proactively identify risk factors and, as a result, develop strategies to improve the prognosis for these patients.

show abstract

“…Over the latest year, a growing body of evidence has demonstrated an increased risk of cardiovascular sequelae after coronavirus disease 2019 (COVID-19) recovery compared with the general population not exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. [1][2][3][4][5][6] The precise pathophysiological mechanisms underlying these heterogeneous clinical manifestations remain largely unknown; however, a primary role seems to be due to persistent inflammation and catabolic state as well as reactivation of latent virus, renin-angiotensin-aldosterone system (RAAS) dysregulation and deep cardiovascular deconditioning. 7,8 Although previous analyses have reported the occurrence of acute pericarditis either during the acute phase of the disease or as a complication of vaccination against COVID-19 disease, [9][10][11][12][13][14] data regarding the risk of pericarditis as postacute COVID-19 sequelae remain scant.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Risk of incident pericarditis after coronavirus disease 2019 recovery: a systematic review and meta-analysis

Zuin,

Imazio,

Rigatelli

et al. 2023

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Aims Data regarding the risk of incident pericarditis in coronavirus disease 2019 (COVID-19) recovered patients are lacking. We determined the risk of incident pericarditis after COVID-19 infection by performing a systematic review and meta-analysis of available data. Methods Following the PRISMA guidelines, we searched MEDLINE and Scopus to locate all articles published up to 11 February 2023 reporting the risk of incident pericarditis in patients who had recovered from COVID-19 infection compared to noninfected patients (controls) defined as those who did not experience the disease over the same follow-up period. Pericarditis risk was evaluated using the Mantel–Haenszel random effects models with hazard ratio (HR) as the effect measure with 95% confidence interval (CI) while heterogeneity was assessed using Higgins I 2 statistic. Results Overall, 16 412 495 patients (mean age 55.1 years, 76.8% males), of whom 1 225 715 had COVID-19 infection, were included. Over a mean follow-up of 9.6 months, pericarditis occurred in 3.40 (95% CI: 3.39–3.41) out of 1000 patients who survived COVID-19 infection compared with 0.82 (95% CI: 0.80–0.83) out of 1000 control patients. Recovered COVID-19 patients presented a higher risk of incident pericarditis (HR: 1.95, 95% CI: 1.56–2.43, I 2: 71.1%) compared with controls. Meta-regression analysis showed a significant direct relationship for the risk of incident pericarditis using HT (P = 0.02) and male sex (P = 0.02) as moderators, while an indirect association was observed when age (P = 0.01) and the follow-up length (P = 0.02) were adopted as moderating variables. Conclusions Recovered COVID-19 patients have a higher risk of pericarditis compared with patients from the general population.

show abstract

Cardiovascular events after COVID-19 hospitalization: long-term follow-up

Cited by 6 publications

References 6 publications

Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality

Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality

Atherosclerosis, Cardiovascular Disease, and COVID-19: A Narrative Review

Risk of incident pericarditis after coronavirus disease 2019 recovery: a systematic review and meta-analysis

Contact Info

Product

Resources

About